Agile Therapeutics Overview
Latest ROE for Agile Therapeutics: 72.37% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow72.37%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Agile Therapeutics's return on equity stands at 72.37%. That is above the Healthcare sector average of 21.28%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Agile Therapeutics sits higher the Healthcare benchmark (21.28%) with a ROE of 72.37%. That is roughly 240.1% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 72.37% for Agile Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Agile Therapeutics's ROE evolved across reporting periods, while the comparison chart places AGRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Agile Therapeutics's reading of 72.37% (sector avg 21.28%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
